UBS Raises Price Target for Legend Biotech to $49 Based on Positive Clinical Data

UBS raised its price target for Legend Biotech (LEGN) from $31 to $49, citing promising clinical progress in the company's LB5006 and LB2501 programs. Early results showed strong therapeutic activity at higher doses with favorable safety profiles.

By Laiba Immad Thu, June 25, 2026 at 3:40 PM GMT+3 2 min read · Yahoo Finance · June 25, 2026, 12:40 UTC

Tickers: $LEGN

Topics: biotech CAR-T healthcare stocks price target upgrade

Read the full article at Yahoo Finance

More World news

IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC
Global Payments Shares Drop 12% Following Reports Private Equity Firms Abandoned Takeover Bid Seeking Alpha · November 12, 2026, 17:14 UTC
Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang's Resignation CNBC · November 12, 2026, 16:59 UTC
Brookfield Corporation Reports Strong Third Quarter Earnings Growth and Increased Share Buybacks Motley Fool · November 12, 2026, 17:08 UTC
Franco-Nevada Reports Q3 2026 Revenue Growth Driven by Higher Gold and Oil Prices Motley Fool · November 12, 2026, 17:10 UTC